Saturday, June 28 Evaluation

Question Title

* 1. Please select your designation(s):

PhD

Other (please specify)

Question Title

* 2. Please indicate your specialties:

Allergy

Asthma

Autoimmunity

Cell Biology

Dermatology

Diabetes

Endocrinology

Flow Cytometry

Gastroenterology

Genetics

Hematology

Infectious Disease

Inflammation

Microbiology

Molecular & Cellular Biology

Multiple Sclerosis

Neuroimmunology

Neurology

Oncology

Pathology

Pharmacology

Primary Immuno-deficiency

Rheumatology

Transplantation

Uveitis

Question Title

* 3. Please select the categories you most identify with:

Trainee/Fellow

Industry

Academic Faculty

Clinician

Question Title

* 4. Saturday, June 28, 8:00-9:30 am
Plenary Session: Checkpoint Control in Disease: Deviating Responses as Therapy

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice as a result of what I learned in this session.	I will make changes in my practice as a result of what I learned in this session. Disagree	I will make changes in my practice as a result of what I learned in this session. Undecided	I will make changes in my practice as a result of what I learned in this session. Agree	I will make changes in my practice as a result of what I learned in this session. Did not attend

Question Title

* 5. After participating in this session, are you able to:

	Yes	No
Describe cancer immunotherapy, targets of immune modulation and PD-L1 and PD-1 pathway.	Describe cancer immunotherapy, targets of immune modulation and PD-L1 and PD-1 pathway. Yes	Describe cancer immunotherapy, targets of immune modulation and PD-L1 and PD-1 pathway. No
Discuss recent advances in T cell exhaustion.	Discuss recent advances in T cell exhaustion. Yes	Discuss recent advances in T cell exhaustion. No
Discuss immune checkpoint blockade for re-invigoration of immunity during infections and cancer.	Discuss immune checkpoint blockade for re-invigoration of immunity during infections and cancer. Yes	Discuss immune checkpoint blockade for re-invigoration of immunity during infections and cancer. No

Question Title

* 6. Please rate the quality of the presentations:

	Excellent	Good	Average	Poor
Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD	Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD Excellent	Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD Good	Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD Average	Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD Poor
Regulating Exhausted T Cell Responses - John Wherry, PhD	Regulating Exhausted T Cell Responses - John Wherry, PhD Excellent	Regulating Exhausted T Cell Responses - John Wherry, PhD Good	Regulating Exhausted T Cell Responses - John Wherry, PhD Average	Regulating Exhausted T Cell Responses - John Wherry, PhD Poor
Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD	Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD Excellent	Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD Good	Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD Average	Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD Poor

Comments

Question Title

* 7. Did you perceive bias in any of the session presentations?

	Yes	No
Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD	Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD Yes	Immune Modulation Therapy Takes on Tumor Microenvironment - Lieping Chen, MD, PhD No
Regulating Exhausted T Cell Responses - John Wherry, PhD	Regulating Exhausted T Cell Responses - John Wherry, PhD Yes	Regulating Exhausted T Cell Responses - John Wherry, PhD No
Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD	Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD Yes	Blockade of Immune Inhibitory Pathways as a Cancer Therapeutic - Tom Gajewski, MD, PhD No

If yes, please specify

Question Title

* 8. Saturday, June 28,10:00-11:30 am
Plenary Session: Biomarkers for Immune Diseases and Transplant Tolerance

	Disagree	Undecided	Agree	Did not attend
I will make changes in my practice/profession as a result of what I learned in this session.	I will make changes in my practice/profession as a result of what I learned in this session. Disagree	I will make changes in my practice/profession as a result of what I learned in this session. Undecided	I will make changes in my practice/profession as a result of what I learned in this session. Agree	I will make changes in my practice/profession as a result of what I learned in this session. Did not attend

Question Title

* 9. After participating in this session, are you able to:

	Yes	No
Describe new insights into the molecular biology of rejection.	Describe new insights into the molecular biology of rejection. Yes	Describe new insights into the molecular biology of rejection. No
Discuss the value of using multi-parameter testing across the autoimmune response to develop tools for stratification and as outcome measures for clinical trials.	Discuss the value of using multi-parameter testing across the autoimmune response to develop tools for stratification and as outcome measures for clinical trials. Yes	Discuss the value of using multi-parameter testing across the autoimmune response to develop tools for stratification and as outcome measures for clinical trials. No
Describe new findings in immune monitoring for co-stimulation blockade and new markers of beta cell decline and clinical responsiveness in type 1 diabetes immunotherapy.	Describe new findings in immune monitoring for co-stimulation blockade and new markers of beta cell decline and clinical responsiveness in type 1 diabetes immunotherapy. Yes	Describe new findings in immune monitoring for co-stimulation blockade and new markers of beta cell decline and clinical responsiveness in type 1 diabetes immunotherapy. No

Question Title

* 10. Please rate the quality of the session presentations:

	Excellent	Good	Average	Poor
The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD	The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD Excellent	The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD Good	The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD Average	The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD Poor
Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD	Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD Excellent	Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD Good	Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD Average	Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD Poor
Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD	Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD Excellent	Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD Good	Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD Average	Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD Poor

Comments

Question Title

* 11. Did you perceive bias in any of the session presentations?

	Yes	No
The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD	The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD Yes	The Molecular Diagnosis of Rejection: Emergence of Molecular Microscope - Philip Halloran, MD, PhD No
Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD	Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD Yes	Immune Monitoring and Stratification in Type 1 Diabetes Therapeutic Trials - Mark Peakman, MD, PhD No
Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD	Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD Yes	Monitoring the Allograft in the 21st Century - Mannikam Suthanthiran, MD No

If yes, please specify

Question Title

* 12. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

CME Certificate

Certificate of Attendance

Please enter your email to receive a certificate

Question Title

* 1. Please select your designation(s):

Question Title

* 2. Please indicate your specialties:

Question Title

* 3. Please select the categories you most identify with:

Question Title

* 4. Saturday, June 28, 8:00-9:30 am Plenary Session: Checkpoint Control in Disease: Deviating Responses as Therapy

Question Title

* 5. After participating in this session, are you able to:

Question Title

* 6. Please rate the quality of the presentations:

Question Title

* 7. Did you perceive bias in any of the session presentations?

Question Title

* 8. Saturday, June 28,10:00-11:30 am Plenary Session: Biomarkers for Immune Diseases and Transplant Tolerance

Question Title

* 9. After participating in this session, are you able to:

Question Title

* 10. Please rate the quality of the session presentations:

Question Title

* 11. Did you perceive bias in any of the session presentations?

Question Title

* 12. If you would like to receive a CME certificate or certificate of attendance, please indicate below.

* 4. Saturday, June 28, 8:00-9:30 am
Plenary Session: Checkpoint Control in Disease: Deviating Responses as Therapy

* 8. Saturday, June 28,10:00-11:30 am
Plenary Session: Biomarkers for Immune Diseases and Transplant Tolerance